Theralase TLTFF Stock
Theralase Price Chart
Theralase TLTFF Financial and Trading Overview
| Theralase stock price | 0.17 USD |
| Previous Close | 0.16 USD |
| Open | 0.16 USD |
| Bid | 0.16 USD x 1500000 |
| Ask | 0.17 USD x 9300000 |
| Day's Range | 0.16 - 0.16 USD |
| 52 Week Range | 0.1 - 0.31 USD |
| Volume | 9K USD |
| Avg. Volume | 185.18K USD |
| Market Cap | 48.49M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.01 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
TLTFF Valuation Measures
| Enterprise Value | N/A |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 56.09208 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Theralase Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 21.42% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 0.31 USD |
| 52 Week Low | 0.1 USD |
| 50-Day Moving Average | 0.21 USD |
| 200-Day Moving Average | 0.17 USD |
TLTFF Share Statistics
| Avg. Volume (3 month) | 185.18K USD |
| Avg. Daily Volume (10-Days) | 312.1K USD |
| Shares Outstanding | 295.67M |
| Float | N/A |
| Short Ratio | N/A |
| % Held by Insiders | 8.40% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | N/A |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | 0.003 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | N/A |
| Diluted EPS (ttm) | -0.01 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | N/A |
| Total Cash Per Share (mrq) | N/A |
| Total Debt (mrq) | N/A |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | N/A |
| Book Value Per Share (mrq) | 0.002923764 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | N/A |
Profile of Theralase
| Country | United States |
| State | ON |
| City | Toronto |
| Address | 41 Hollinger Road |
| ZIP | M4B 3G4 |
| Phone | 416 699 5273 |
| Website | https://www.theralase.com |
| Industry | Medical Devices |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops, manufactures, and markets super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has a collaboration with the National Microbiology Laboratory, a Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. Theralase Technologies Inc. is based in Toronto, Canada.
Q&A For Theralase Stock
What is a current TLTFF stock price?
Theralase TLTFF stock price today per share is 0.17 USD.
How to purchase Theralase stock?
You can buy TLTFF shares on the OTC Markets OTCQB exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Theralase?
The stock symbol or ticker of Theralase is TLTFF.
Which industry does the Theralase company belong to?
The Theralase industry is Medical Devices.
How many shares does Theralase have in circulation?
The max supply of Theralase shares is 275.82M.
What is Theralase Price to Earnings Ratio (PE Ratio)?
Theralase PE Ratio is now.
What was Theralase earnings per share over the trailing 12 months (TTM)?
Theralase EPS is -0.01 USD over the trailing 12 months.
Which sector does the Theralase company belong to?
The Theralase sector is Healthcare.